Young-Sun Sohn
Corporate Officer/Principal bei Catholic University of Korea
Profil
Young-Sun Sohn is a Professor at Catholic University of Korea.
Previously, he worked as the Chief Executive Officer at Abxign, Inc., Director-Biotechnology Research Center at Daewoong Pharmaceutical Co., Ltd., and Principal Scientist at CJ Corp.
Aktive Positionen von Young-Sun Sohn
Unternehmen | Position | Beginn |
---|---|---|
Catholic University of Korea | Corporate Officer/Principal | 15.09.2011 |
Ehemalige bekannte Positionen von Young-Sun Sohn
Unternehmen | Position | Ende |
---|---|---|
Abxign, Inc.
Abxign, Inc. Pharmaceuticals: MajorHealth Technology Abxign, Inc. was established in January 2008 and is located in Samsung Cancer Research building in Seoul National University. Abxign focused on the discovery and development of antibody therapeutics where by first or best-in-class therapies are introduced in large and growing markets with quality partners. Abxign has accumulated therapeutic antibody development technology and experience for many years and maintains relationships with domestic and foreign pharmaceutical companies specialized for each part of the development of antibody therapy. Based on these Abxign's network and technology, it will release the excellent antibodies in the world pharmaceutical market and extend the human life and contribute to improving the quality of life. | Präsident | 25.07.2013 |
CJ CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | - |
DAEWOONG PHARMACEUTICAL CO., LTD | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
CJ CORPORATION | Consumer Non-Durables |
DAEWOONG PHARMACEUTICAL CO., LTD | Health Technology |
Private Unternehmen | 1 |
---|---|
Abxign, Inc.
Abxign, Inc. Pharmaceuticals: MajorHealth Technology Abxign, Inc. was established in January 2008 and is located in Samsung Cancer Research building in Seoul National University. Abxign focused on the discovery and development of antibody therapeutics where by first or best-in-class therapies are introduced in large and growing markets with quality partners. Abxign has accumulated therapeutic antibody development technology and experience for many years and maintains relationships with domestic and foreign pharmaceutical companies specialized for each part of the development of antibody therapy. Based on these Abxign's network and technology, it will release the excellent antibodies in the world pharmaceutical market and extend the human life and contribute to improving the quality of life. | Health Technology |